Published Date : Nov 17, 2015
Type 2 diabetics with CVD who were given the anti-diabetic sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin were observed to have a reduced risk of a heart failure or risk of death due to CVD. This observed in a trial follow-up of 3.1 years. The trial look partly positive as it is surely reducing the possibility of associated heart failure, a concern that has been rising one amongst diabetics. These patients were compared with a set of other patients who were given a placebo.
Dr Silvio E Inzucchi, Yale University School of Medicine, New Haven, CT stated that the empagliflozin benefited the high-risk patients. This finding was presented from a pre-specified secondary analysis of the EMPA-REG OUTCOME trial being conducted at the American Heart Association (AHA) 2015 Scientific Sessions. However, the reaction of the audience to this statistic was quite measured.
The main finding of the trial emphasized that the patients were given empagliflozin had a 38% less chances of losing their life to CVD and 35% lesser chance of hospitalization for HF as compared to the ones who have been taking placebo in the past 3.1 years.
According to Dr Donald M Lloyd-Jones, co-chair at AHA press meet stated that metformin will remain the first choice for oral therapy for patients who are diagnosed with type 2 diabetes. He further added that there are a range of diabetes medications that have several agents effectively working towards lowering blood glucose levels and thereby reducing the patient’s risk of retinopathy, neuropathy, and nephropathy.